Language:
Password reminder
No account yet? Register Free
About Us Advertising Info Contact Us Client Login
labmedica.com
Lab Technology
Features Subscription Partner Sites Journal Info
AB SCIEXRANDOX LABORATORIESVeolia WATER

Digital PCR Chosen to Develop Leukemia Test

By Labmedica International staff writers
Posted on 04 Feb 2013


A general method called “limiting dilution polymerase chain reaction (PCR)” was developed for quantifying PCR targets. This method was subsequently used for the quantification of marker mutations in acute leukemia.

By diluting DNA samples so that only one or two copies per well were present and then amplifying those copies with PCR, scientists were able to detect two copies of leukemic DNA against a background of 160,000 normal genomes.

The team then reported that the outcome of acute leukemia can be predicted by measuring the response to treatment using limiting dilution PCR to quantify the leukemic cells at high sensitivity. Prof. Alec Morley and his lab at Flinders University and Medical Center in Adelaide (SA, Australia) then used real-time quantitative PCR (qPCR) to develop a highly sensitive method for isolating and quantifying the chromosomal translocation that is typically associated with chronic myelogenous (or myeloid) leukemia (CML), also known as chronic granulocytic leukemia (CGL), a cancer of the white blood cells. It is a form of leukemia characterized by the increased and unregulated growth of predominantly myeloid cells in the bone marrow and the accumulation of these cells in the blood.

Because the translocation point for each patient is different in CML, real-time PCR conditions may vary from patient to patient and may therefore produce different results. Therefore, real-time PCR conditions may vary from patient to patient and may therefore produce different results. The lab has now returned to digital PCR.

Monoquant, a company associated with Flinders University, used Bio-Rad’s (Hercules, CA, USA) QX100 system to refine the new clinical test for CML. Not only does the instrument offer high sensitivity but also removes variability in amplification efficiency that results from using patient-specific PCR primers, a traditional sticking point for the US Food and Drug Administration (FDA; Silver Spring, MD, USA). Monoquant hopes the results from the QX100 system will fast-track the FDA approval process for its test.

Related Links:
Flinders University and Medical Center in Adelaide, South Australia
Monoquant
Bio-Rad






Pipette Controller
Pipette Controller
Chemistry System
Chemistry System
Clinical Chemistry Analyzer
Clinical Chemistry Analyzer

More Products

CELLAVISION AB

Latest Lab Technology News

LinkXpress
Click for LinkXpress
Reader Inquiry Service
Enter code to receive information:
Where I can find code?
Featured Whitepaper
SIEMENS DIAGNOSTICS :
Siemens Healthcare Diagnostics Anti-CCP: A Clinical Evaluation Whitepaper

Download Whitepaper
Events
ELA – European Lab Automation congress
06 Jun 2013 - 07 Jun 2013


European Human Genetics Conference 2013
08 Jun 2013 - 11 Jun 2013


8th Forum on Oxidative Stress and Aging
12 Jun 2013 - 14 Jun 2013


More events
GLOBETECH PUBLISHING
Latest Issue

View Digital Edition
Subscribe / Renew
BioConferenceLive'
GREINER-BIO-ONE
ALTO MARKETING LIMITED
KARL HECHT GMBH & CO KG
DIASOURCE
BioPorto Diagnostics
77 ELEKTRONIKA
AACC
  labmedica.com Copyright © 2000-2013 Globetech Media. All rights reserved.
Privacy Policy